Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947946382> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2947946382 endingPage "9502" @default.
- W2947946382 startingPage "9502" @default.
- W2947946382 abstract "9502 Background: Adjuvant anti-PD1 monoclonal antibodies (mAbs) prolong recurrence-free survival in high-risk resected melanoma, however patients (pts) recur during or after therapy. The patterns of recurrence and optimal management are unclear. Methods: Pts from 15 melanoma centres who recurred having received adjuvant anti-PD1 mAbs (adj-PD1) for resected stage III/IV cutaneous melanoma were included. Disease characteristics, adjuvant treatment, recurrence characteristics, subsequent management and outcomes were examined. Results: 137 pts had melanoma recurrence; 97 (71%) during adj-PD1 and 40 (29%) following treatment cessation (25 had stopped early for toxicity after a median 3 months, 14 after completing 12 months, 1 who withdrew consent after 1 month). Median time to recurrence from start of anti-PD1 was 4.6 months (IQR 2.7-8.5), and median follow up from recurrence was 7.7 months (IQR 3.8-12.3). At 1st recurrence, 78 (57%) pts had distant disease (including 22 with both locoregional and distant), 59 (43%) had locoregional disease only. Of those who recurred locally, 22/59 (37%) later developed distant disease. 26 (19%) pts have died. 81 (59%) pts had systemic therapy for distant recurrence (either 1 st recurrence or subsequent). Of those who recurred during adj-PD1, no pts (0/20) subsequently responded to anti-PD1 alone (N = 8) or with any investigational agent (N = 12; anti-LAG3, IDOi, MEKi, TLR9 agonist); 9/27 evaluable pts (33%) responded to ipilimumab-based therapy (alone or in combination with anti-PD1), and 15/19 (79%) responded to BRAF/MEKi . Of those who recurred after ceasing adj-PD1, 2/5 (40%) responded to anti-PD1 monotherapy, 2/5 (40%) responded to ipilimumab-based therapy, 7/8 (88%) responded to BRAF/MEKi. Conclusions: These data suggest minimal activity of further anti-PD1 monotherapy in those who recur while on adj-PD1, but possible activity in those who recur off treatment. Anti-CTLA4 and BRAF/MEKi therapy appear active in those who recur on or following adj-PD1. Data on locoregional recurrence and its management will also be presented." @default.
- W2947946382 created "2019-06-07" @default.
- W2947946382 creator A5002640207 @default.
- W2947946382 creator A5004888437 @default.
- W2947946382 creator A5018950341 @default.
- W2947946382 creator A5022520811 @default.
- W2947946382 creator A5035218748 @default.
- W2947946382 creator A5036642494 @default.
- W2947946382 creator A5037399273 @default.
- W2947946382 creator A5037535482 @default.
- W2947946382 creator A5040291209 @default.
- W2947946382 creator A5040969461 @default.
- W2947946382 creator A5054979658 @default.
- W2947946382 creator A5055038393 @default.
- W2947946382 creator A5070576000 @default.
- W2947946382 creator A5073133122 @default.
- W2947946382 creator A5076054848 @default.
- W2947946382 creator A5079833339 @default.
- W2947946382 creator A5080176242 @default.
- W2947946382 creator A5082278497 @default.
- W2947946382 creator A5083061830 @default.
- W2947946382 creator A5088390068 @default.
- W2947946382 date "2019-05-20" @default.
- W2947946382 modified "2023-09-30" @default.
- W2947946382 title "A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy." @default.
- W2947946382 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.9502" @default.
- W2947946382 hasPublicationYear "2019" @default.
- W2947946382 type Work @default.
- W2947946382 sameAs 2947946382 @default.
- W2947946382 citedByCount "5" @default.
- W2947946382 countsByYear W29479463822019 @default.
- W2947946382 countsByYear W29479463822020 @default.
- W2947946382 countsByYear W29479463822021 @default.
- W2947946382 crossrefType "journal-article" @default.
- W2947946382 hasAuthorship W2947946382A5002640207 @default.
- W2947946382 hasAuthorship W2947946382A5004888437 @default.
- W2947946382 hasAuthorship W2947946382A5018950341 @default.
- W2947946382 hasAuthorship W2947946382A5022520811 @default.
- W2947946382 hasAuthorship W2947946382A5035218748 @default.
- W2947946382 hasAuthorship W2947946382A5036642494 @default.
- W2947946382 hasAuthorship W2947946382A5037399273 @default.
- W2947946382 hasAuthorship W2947946382A5037535482 @default.
- W2947946382 hasAuthorship W2947946382A5040291209 @default.
- W2947946382 hasAuthorship W2947946382A5040969461 @default.
- W2947946382 hasAuthorship W2947946382A5054979658 @default.
- W2947946382 hasAuthorship W2947946382A5055038393 @default.
- W2947946382 hasAuthorship W2947946382A5070576000 @default.
- W2947946382 hasAuthorship W2947946382A5073133122 @default.
- W2947946382 hasAuthorship W2947946382A5076054848 @default.
- W2947946382 hasAuthorship W2947946382A5079833339 @default.
- W2947946382 hasAuthorship W2947946382A5080176242 @default.
- W2947946382 hasAuthorship W2947946382A5082278497 @default.
- W2947946382 hasAuthorship W2947946382A5083061830 @default.
- W2947946382 hasAuthorship W2947946382A5088390068 @default.
- W2947946382 hasConcept C121608353 @default.
- W2947946382 hasConcept C126322002 @default.
- W2947946382 hasConcept C141071460 @default.
- W2947946382 hasConcept C2776694085 @default.
- W2947946382 hasConcept C2777658100 @default.
- W2947946382 hasConcept C2777701055 @default.
- W2947946382 hasConcept C2777863537 @default.
- W2947946382 hasConcept C2777982462 @default.
- W2947946382 hasConcept C2781433595 @default.
- W2947946382 hasConcept C502942594 @default.
- W2947946382 hasConcept C71924100 @default.
- W2947946382 hasConcept C90924648 @default.
- W2947946382 hasConceptScore W2947946382C121608353 @default.
- W2947946382 hasConceptScore W2947946382C126322002 @default.
- W2947946382 hasConceptScore W2947946382C141071460 @default.
- W2947946382 hasConceptScore W2947946382C2776694085 @default.
- W2947946382 hasConceptScore W2947946382C2777658100 @default.
- W2947946382 hasConceptScore W2947946382C2777701055 @default.
- W2947946382 hasConceptScore W2947946382C2777863537 @default.
- W2947946382 hasConceptScore W2947946382C2777982462 @default.
- W2947946382 hasConceptScore W2947946382C2781433595 @default.
- W2947946382 hasConceptScore W2947946382C502942594 @default.
- W2947946382 hasConceptScore W2947946382C71924100 @default.
- W2947946382 hasConceptScore W2947946382C90924648 @default.
- W2947946382 hasIssue "15_suppl" @default.
- W2947946382 hasLocation W29479463821 @default.
- W2947946382 hasOpenAccess W2947946382 @default.
- W2947946382 hasPrimaryLocation W29479463821 @default.
- W2947946382 hasRelatedWork W1996336352 @default.
- W2947946382 hasRelatedWork W2013259535 @default.
- W2947946382 hasRelatedWork W2056489416 @default.
- W2947946382 hasRelatedWork W2189560216 @default.
- W2947946382 hasRelatedWork W2395564121 @default.
- W2947946382 hasRelatedWork W2397756962 @default.
- W2947946382 hasRelatedWork W2752227448 @default.
- W2947946382 hasRelatedWork W2805129282 @default.
- W2947946382 hasRelatedWork W2884153854 @default.
- W2947946382 hasRelatedWork W3045341250 @default.
- W2947946382 hasVolume "37" @default.
- W2947946382 isParatext "false" @default.
- W2947946382 isRetracted "false" @default.
- W2947946382 magId "2947946382" @default.
- W2947946382 workType "article" @default.